Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Pentobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.51 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentobarbital SCHEMBL477033 | 0.96 | CYP3A4 (0.50) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL11435733 | 0.95 | CYP3A4 (0.49) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL2689394 | 0.95 | CYP3A4 (0.49) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL6489504 | 0.95 | CYP3A4 (0.49) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL10727223 | 0.95 | CYP3A4 (0.51) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL7768612 | 0.94 | CYP3A4 (0.54) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL7033991 | 0.94 | CYP3A4 (0.57) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL9221628 | 0.94 | CYP3A4 (0.57) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL1247 | 0.94 | CYP3A4 (0.57) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 | |
| Pentobarbital SCHEMBL23496511 | 0.94 | CYP3A4 (0.48) | CYP3A4KDM4EALDH1A1GABRB3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112240239-A | Compression ignition internal combustion engine using reactive agent | 周氏（北京）汽车技术有限公司 | 2021-01-19 | — | — | CN | claimed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250315159-A1 | TOUCH DETECTION DEVICE WITH TOUCH INTERFACE MADE OF COMPOSITE MATERIAL | SAS WOODOO (FR) | 2025-10-09 | — | — | US | disclosed |
| WO-2025055580-A1 | NEGATIVE ELECTRODE SHEET AND LITHIUM ION BATTERY COMPRISING SAME | 珠海冠宇电池股份有限公司 | 2025-03-20 | — | — | WO | disclosed |
| EP-4478433-A1 | NEGATIVE ELECTRODE SHEET, SECONDARY BATTERY AND ELECTRICAL DEVICE | CALB Group Co., Ltd. (CN) | 2024-12-18 | — | — | EP | disclosed |
| US-20240379939-A1 | NEGATIVE ELECTRODE SHEET, SECONDARY BATTERY AND ELECTRICAL DEVICE | CALB Group Co., Ltd. (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2024226691-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240301388-A1 | DELIGNIFIED BAMBOO SCAFFOLDS INCLUDING IMMOBILIZED ENZYMES AND METHODS FOR FORMING AND USING SAME | UNIVERSITY OF SOUTH CAROLINA | 2024-09-12 | — | — | US | disclosed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| EP-3656520-B1 | METHOD FOR PARTIAL DELIGNIFICATION AND FILLING OF A LIGNOCELLULOSIC MATERIAL, AND COMPOSITE MATERIAL STRUCTURE OBTAINED BY SAID METHOD | SAS WOODOO (FR) | 2023-11-01 | — | — | EP | disclosed |
| US-20180370071-A1 | PROCESS FOR PARTIAL DELIGNIFICATION AND FILLING OF A LIGNOCELLULOSIC MATERIAL, AND COMPOSITE MATERIAL STRUCTURE ABLE TO BE OBTAINED BY THIS PROCESS | SAS WOODOO (FR) | 2018-12-27 | — | — | US | disclosed |
| US-20180191033-A1 | ELECTROLYTE ADDITIVES FOR ELECTROCHEMICAL DEVICES | NATRON ENERGY, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| EP-2248542-A2 | Polycarbonate polyurethane venous access devices having enhanced strength | Navilyst Medical, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100256546-A1 | Polycarbonate Polyurethane Venous Access Devices Having Enhanced Strength | NAVILYST MEDICAL, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-1667694-B1 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20080070155-A1 | INCLUSION COMPLEX, PHOTORESIST COMPOSITION HAVING THE INCLUSION COMPLEX AND METHOD OF FORMING A PATTERN USING THE PHOTORESIST COMPOSITION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-03-20 | — | — | US | disclosed |
| US-20060063760-A1 | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1620397-A1 | HYDROXAMIC ACIDS USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004094376-A1 | HYDROXAMIC ACIDS USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-3992453-A | Hydroformylation process | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063760-A1 | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | MKI67, PCNA, CCNA1 | GABRB3 3492/4885GABRA2 3621/4885GABRB2 3292/4885 |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | GABRB3 3342/4885GABRA2 4039/4885GABRB2 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.